Literature DB >> 28609111

Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials.

Anna J Podolanczuk1, David J Lederer1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28609111      PMCID： PMC5803654          DOI： 10.1164/rccm.201705-0975ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  7 in total

1.  Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

Authors:  Banu A Karimi-Shah; Badrul A Chowdhury
Journal:  N Engl J Med       Date:  2015-03-26       Impact factor: 91.245

2.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

3.  Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.

Authors:  Brett Ley; Jeffrey Swigris; Bann-Mo Day; John L Stauffer; Karina Raimundo; Willis Chou; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

4.  Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.

Authors:  Ganesh Raghu; Harold R Collard; Kevin J Anstrom; Kevin R Flaherty; Thomas R Fleming; Talmadge E King; Fernando J Martinez; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2012-04-13       Impact factor: 21.405

5.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

6.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

7.  Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.

Authors:  Roland M du Bois; Steven D Nathan; Luca Richeldi; Marvin I Schwarz; Paul W Noble
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.